A PROSPECTIVE STUDY OF ANTI-HCV POSITIVE BLOOD DONORS

大约0.6%的志愿捐献者被发现 有丙型肝炎病毒抗体（抗HCV），主要原因 输血相关性肝炎（TAH） 有些捐赠者是真的 通过重组免疫印迹测定（RIBA）确定为阳性， 是假阳性，有些是RIBA不确定的。 本研究将 每个RIBA至少招募100名抗HCV阳性供体 分类并比较HCV感染的流行病学危险因素， 相关肝病的程度。 初步分析显示， 至少60%的RIBA阳性供体具有公认的胃肠外风险 因素，主要是IV药物使用，而对照组不到5%。 这些风险因素本应将这些人排除在捐赠之外， 但没有这样做，这表明需要修改供体筛选 程序. 大量无症状RIBA阳性供体 慢性肝炎的生化证据。

Approximately 0.6% of the volunteer donor population has been found to have antibody to the hepatitis C virus (anti-HCV), the predominant cause of transfusion associated hepatitis (TAH). Some of the donors are true positive as determined by a recombinant immunoblot assay (RIBA) and some are false positives and some are RIBA indeterminate. This study will enroll at least 100 anti-HCV positive donors in each of the RIBA categories and compare epidemiologic risk factors for HCV acquisition and the extent of associated liver disease. Preliminary analysis reveals that at least 60% of RIBA positive donors have recognized parenteral risk factors, primarily IV drug use compared to less than 5% of controls. These risk factors should have excluded these individuals from donation, but failed to do so indicating the need for revision of donor screening procedures. A large number of asymptomatic RIBA positive donors have biochemical evidence of chronic hepatitis.